NEOGENOMICS INC 8-K

What Happened

• On June 15, 2026, NeoGenomics, Inc. announced the commencement of a proposed offering of convertible senior notes due 2032. The offering is being made to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act. The company filed a press release about the offering as Exhibit 99.1 to the Form 8-K. The 8-K notes that this filing and the attached release do not constitute an offer to sell or a solicitation in any jurisdiction where unlawful.

Key Details

• Date of announcement: June 15, 2026.
• Security: Convertible senior notes due 2032.
• Target investors: Qualified Institutional Buyers under Rule 144A.
• Disclosure: Press release filed as Exhibit 99.1; offering size, interest rate, conversion terms and use of proceeds were not disclosed in this Form 8-K.
• Form 8-K signed by Alicia C. Olivo, Executive VP, General Counsel & Secretary.

Why It Matters

• This is a financing action that will add debt to NeoGenomics’ capital structure and, because the notes are convertible, could lead to future share issuance if converted—both outcomes can affect existing shareholders.
• Key commercial and financial terms (size, pricing, conversion mechanics, and planned use of proceeds) were not included in this filing; investors should watch for follow-on disclosures, pricing notices, or registration statements that provide those material details.
• The offering is limited to institutional buyers under Rule 144A, so retail investors cannot directly participate in the initial placement.